Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Syntara Limited ( (AU:SNT) ) has shared an update.
Syntara Limited announced positive results from its Phase 2a trial of amsulostat in myelofibrosis, showing significant symptom improvement and spleen volume reduction in patients, with no serious adverse events. The company is advancing its clinical pipeline with new trials and strategic appointments, positioning itself strongly in the blood-cancer and dermatology markets.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Syntara Limited stock, see the AU:SNT Stock Forecast page.
More about Syntara Limited
Syntara Limited is a clinical-stage drug development company focused on creating innovative therapies for various medical conditions. The company is involved in the development of treatments for myelofibrosis, myelodysplastic neoplasms, and dermatological conditions such as hypertrophic and keloid scars.
Average Trading Volume: 5,061,432
Technical Sentiment Signal: Sell
Current Market Cap: A$50.6M
Find detailed analytics on SNT stock on TipRanks’ Stock Analysis page.